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Abstract
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PFOS is a chemical of nearly ubiquitous exposure in humans. Recent studies have associated
PFOS exposure to adipose tissue-related effects. The present study was to determine whether
PFOS alters the process of adipogenesis and regulates insulin-stimulated glucose uptake in mouse
and human preadipocytes. In murine-derived 3T3-L1 preadipocytes, PFOS enhanced hormoneinduced differentiation to adipocytes and adipogenic gene expression, increased insulin-stimulated
glucose uptake at concentrations ranging from 10 to 100 µM, and enhanced Glucose transporter
type 4 and Insulin receptor substrate-1 expression. Nuclear factor (erythroid-derived 2)-like 2
(Nrf2), NAD(P)H dehydrogenase, quinone 1 and Glutamate-cysteine ligase, catalytic subunit were
significantly induced in 3T3-L1 cells treated with PFOS, along with a robust induction of
Antioxidant Response Element (ARE) reporter in mouse embryonic fibroblasts isolated from
ARE-hPAP transgenic mice by PFOS treatment. Chromatin immunoprecipitation assays further
illustrated that PFOS increased Nrf2 binding to ARE sites in mouse Nqo1 promoter, suggesting
that PFOS activated Nrf2 signaling in murine-derived preadipocytes. Additionally, PFOS
administration in mice (100 µg/kg/day) induced adipogenic gene expression and activated Nrf2
signaling in epididymal white adipose tissue. Moreover, the treatment on human visceral
preadipocytes illustrated that PFOS (5 and 50 µM) promoted adipogenesis and increased cellular
lipid accumulation. It was observed that PFOS increased Nrf2 binding to ARE sites in association
with Nrf2 signaling activation, induction of Peroxisome proliferator-activated receptor γ and
CCAAT/enhancer-binding protein α expression, and increased adipogenesis. This study points to
a potential role PFOS in dysregulation of adipose tissue expandability, and warrants further
investigations on the adverse effects of persistent pollutants on human health.
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Perfluorooctane sulfonate (C8HF17O3S, PFOS) and Perfluorooctanoic acid (C8HF15O2,
PFOA) are organic fluoroalkyl chemicals widely used in industrial and consumer
applications as powerful surfactants and building material components, as they are stable at
high temperature and nonflammable (Olsen et al., 2005). These two chemicals have been
detected worldwide in the environment, including drinking water (Skutlarek et al., 2006),
atmosphere air (Shoeib et al., 2005), soil, sediments (Boulanger et al., 2005), and even the
wildlife in the Antarctic Pole (Giesy and Kannan, 2001). Average human serum PFOS and
PFOA content has decreased between 2000 and 2005 due to the phase out of
Perfluorooctanesulfonyl-fluoride (POSF, C8F17SO2F)-based materials by the primary
global manufacturer, 3M Company, in May 2000 (Olsen et al., 2007b), but the related health
effects still remain a concern. Although have been banned in United States and Europe,
PFOS and PFOS-related chemicals are still currently produced in China.
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Importantly, PFOS and PFOA are readily absorbed and poorly eliminated from humans.
Increased renal absorption via transport mechanisms is suspected to be the mechanism that
contributes to the relatively long serum half-lives observed in humans (Olsen et al., 2007a),
which has been estimated to 5.4 (PFOS) and 3.8 (PFOA) years. Because of its persistence in
the body and presence in populations across the world, it is important to assess potential
health effects. Liver is the major organ affected by exposure of PFOS in animal models. It is
known that PFOS will be deposited in liver, which associated with increased liver weight in
rats, mice, and monkeys (Chang et al., 2012; Wan et al., 2012). Exposure of PFOS has been
shown to induce further undesirable effects, such as increased hepatic lipid accumulation
along with significant induction of Cluster of differentiation 36 (FAT/CD36) and
Lipoprotein lipase (Lpl) expression, which resulted in disturbance of lipid metabolism and
excessive fatty liver (Wan et al., 2012). In addition, dietary administration of PFOS in mice
(0.005%, w/w) for 10 days reduced serum cholesterol and triglycerides levels, and induced a
moderate hepatomegaly (Qazi et al., 2010). More recent publications reported that exposure
of PFOS altered expression of genes mainly involved in lipid modulation, energy
metabolism, reproduction, hormone regulation, suggesting a role for PFOS in regulating
lipid metabolism and development (Hu et al., 2005; Hagenaars et al., 2008). The observed
hepatomegaly that results from PFOS administration is due to Peroxisome proliferatoractivated receptor (Ppar) activation (Takacs and Abbott, 2007; Bjork and Wallace, 2009).
Rosen et al. also reported that PFOS may modulate various gene expression related to lipid
metabolism, inflammation, and xenobiotic metabolism via Pparα-independent mechanisms,
such as the modest activation of Constitutive Androstane Receptor (CAR) and Pparγ
signaling pathway (Rosen et al., 2010). And PFOA was reported to induce various
xenobiotic metabolism genes, which were under the control of CAR and transcription factor
of Nuclear factor erythoid 2-related factor 2 (Nrf2) (Rosen et al., 2008). However, PFOS
effects on adipogenesis and white adipose tissue (WAT) expansion were still unknown.
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Adipogenesis is a process involving sequential coordinated gene induction (Rosen and
Spiegelman, 2000). CCAAT/enhancer-binding protein (Cebp) δ and Cebpβ induce the
expression of Pparγ, which activates Cebpα expression, and these two transcriptional factors
of Pparγ and Cebpα can work in concert to maintain the differentiated status. Subsequently,
Pparγ and Cebpα activation induce the subsequent steps of adipogenesis and lipogenesis.
Gain-of-function experiments that forced Pparγ and/or in combination with potential
agonists demonstrated that non-adipogenic, fibroblast cells can be transdifferentiated to
adipocytes (Wu et al., 1995). Emerging data points to new regulators of Ppar signaling
pathway, such as transcription factor of Nrf2, regulated lipid metabolism and the process of
adipogenesis (Shin et al., 2007; Pi et al., 2010). Classically, Nrf2 binds to AntioxidantResponsive Elements (ARE), induces expression of a battery of detoxification and
antioxidant genes to counter cellular electrophilic and oxidative stress (Kensler et al., 2007;
Klaassen and Reisman, 2010). Pi et al. reported that an ARE element exists in mouse Pparγ
promoter, and loss of Nrf2 reduced Pparγ expression and prevented the process of
adipogenesis in 3T3-L1 preadipocytes (Pi et al., 2010). This work provided a link between
Nrf2 and adipogenesis. Other studies have demonstrated that too much Nrf2 activation can
also perturb adipogeneis. An early study by Kensler et al. described Nrf2 prevented
adipogenesis via modulating Aryl hydrocarbon receptor Signaling (Shin et al., 2007). Our
previous results demonstrated that enhanced Nrf2 activity via Kelch-like ECH-associated
protein 1 - knockdown (Keap1-KD) inhibited WAT expansion and the adipocyte
differentiation, suggesting the Nrf2-independent mechanism involved in Keap1-KD system
(Xu et al., 2012). The relationship of PFOS and Nrf2 has been reported in zebrafish in 2010.
In the publication, the authors reported that PFOS increased cellular ROS content.
Activation of Nrf2 signaling by sulforaphane reduced ROS content, further reduced MAPK
activation of JNK and p38 signaling, suggesting that Nrf2 signaling regulated PFOS-induced
oxidative stress (Shi and Zhou, 2010).
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To evaluate the effect of PFOS on adipogenesis, and further explore its effects on regulating
WAT expansion and the development of obesity, 3T3-L1 preadipocytes were induced to
differentiation to adipocytes with the presence of PFOS with the dose of environmental
exposure-relevant concentrations. The cellular lipid content and adipogenic gene expression
were evaluated. Additionally, glucose uptake was determined in the mature adipocytes with
PFOS administration. Lastly, PFOS-induced adipogenic effects were also evaluated in a
whole animal model with daily PFOS administration and in human visceral preadipocytes.
The current study demonstrates that PFOS induces Nrf2 activation in association with
promoting Pparγ and Cebpα signaling, and induction of adipogenesis that increases lipid
accumulation in 3T3-L1 preadipocytes. Moreover, pro-adipogenic effects were observed in
human visceral preadipocytes exposed to PFOS.

Material and Methods
Chemicals
Heptadecaperfluorooctanesulfonic acid potassium salt (#77282, PFOS), insulin (#I6634),
dexamethasone (#D4902, DEX) isobutylmethylxanthine (#I5879, IBMX), and Oil Red O
(#O0625) were got from Sigma-Aldrich (St. Louis, MO). Ethanol, methanol, isopropanol,
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MTT solution and other chemicals without specific illustration were got from Thermo Fisher
Scientific Inc. (Waltham, MA)
Animals and PFOS administration
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10-week-old male C57BL/6 mice weighing approximately 30 grams were purchased from
Charles River Laboratories (Wilmington, MA). The mice were housed under a controlled
temperature (22–25 °C) with relative humidity (30–70%), lighting (12 hrs, light-dark cycles)
environment and acclimated for 5 weeks on the standard rodent chow to allow for additional
weight gain. At 15 weeks of age, the mice were then fed a purified rodent chow (AIN-93G
Growth Purified Diet, TestDiet, St. Louis, MO). At 21 weeks of age, mice (n=8) were
administered water as vehicle via oral gavage (5 mL/kg) or PFOS (100 µg/kg, 5 mL/kg) for
36 days. Body weight and food intake were monitored daily and recorded. Epididymal WAT
was collected, snap frozen with liquid nitrogen, and stored at −70 °C until analysis. All
procedures were conducted in accordance with the NIH Guidelines for the Care and Use of
Laboratory Animals and were approved by the University of Rhode Island Animal Care and
Use Committee.
Acute cytotoxicity assay

Author Manuscript

A minimum of 5 replicates of 7,500 3T3-L1 preadipocytes per well were plated in 96-well
plates and allowed to adhere to the plate for approximately 12 hrs, at which time the media
was removed and replaced with fresh media containing varying concentrations of PFOS in
DMSO (1 nM, 5 nM, 10 nM, 100 nM, 500 nM, 1 µM, 5 µM, 10 µM, 50 µM, 100 µM). Cells
were subsequently incubated for an additional 48 hrs. Then 20 µL MTT solution (5 mg/mL
in PBS) was added and the plate was incubated for another 3 hrs. The supernatant was
removed carefully and 150 µL MTT solvent (4 mM HCl, 0.1% NP-40 in isopropanol) was
added to each well. The plate was covered with foil and agitated on an orbital shaker for 15
mins. The cell viability was determined by measuring the absorbance at 590 nm with 620
nm as reference filter. Relative cell viability (%) was displayed using vehicle (0.1%
DMSO)-treated samples as a standard.
Cell culture and 3T3-L1 pre-adipocyte differentiation

Author Manuscript

Mouse 3T3-L1 (ATCC® CL-173™) preadipocytes were obtained from ATCC (American
Type Culture Collection, Manassas, VA, USA) and maintained in high-glucose DMEM
medium supplemented with 10% fetal bovine serum (FBS). 3T3-L1 preadipocyte
differentiation was induced according to the protocol described previously (Shin et al.,
2007; Xu et al., 2012). Briefly, 2 days post 100% confluence, 3T3-L1 preadipocytes were
stimulated to differentiation to adipocytes in a standard adipogenic differentiation medium
(DMEM containing 10% FBS, 10 µg/mL insulin, 1 µM DEX, 0.5 mM IBMX), which was
considered Day0. Cells were cultured in the latter media for Days 0–3 and then cultured in
DMEM containing 10% FBS and 10 µg/mL insulin for the remaining days. Media was
refreshed every 2 days. Cell treatment and corresponding assay were described as Figure
1A.
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Poietics™ Human visceral preadipocytes (Donor #: 24711; Lot #:0000313366; Cat #:
PT-5005) were obtained from Lonza (Lonza Walkersville, Inc., Walkersville, MD) and
maintained in PBM-2 media according to the manufacturer’s instructions. The preadipocytes
were plated at 8,700 cells per well. Cells were induced to differentiation to adipocytes by
switching with the differentiated media of PBM-2 supplementing with dexamethasone,
isobutylmethylxanthine and insulinSingleQuots™ 24 hrs post 100% confluence and keep in
the same media for the next 11 days. Cells were treated with DMSO (0.1%) or PFOS (5 or
100 µM) in quadruplicates. Oil red O was used to image the lipid droplets. The cellular lipid
was purified via isopropanol extraction and the lipid content was quantified
spectrophotometrically at what 520 nm. Cell treatment and corresponding assay were
described as Figure 1B.
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RNA isolation and quantitative real-time PCR
Total RNA was isolated using TRIzol reagent (Invitrogen, CA) according to the
manufacturer’s instructions. One microgram of total RNA was converted to cDNA and
mRNA levels were quantified by quantitative real-time PCR using a Roche LightCycler 480
System (Roche Applied Science, Mannheim, Germany). SYBR green chemistry was used
and relative target gene expression was normalized to 18S rRNA. The primers used are
listed in Supplementary Table 1.
Oil Red O staining
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3T3-L1 preadipocytes or human visceral preadipocytes were induced to differentiation to
adipocytes. The supernatant was removed and cell layer was washed twice with 2 mL icecold PBS. Cells were fixed with 10% formalin at 4 °C for 30 mins, then stained with Oil
Red O solution (six parts Oil Red O stock solution [0.5% Oil Red O in 100% isopropanol]
and four parts H2O) for 60 mins. Cells were counterstained with hematoxylin and mounted
in glycerin jelly (Carolina Biological Supply Company, Burlington, NC).
Measurement of triglycerides in 3T3-L1 preadipocytes
3T3-L1 preadipocytes plated on 60-mm dishes were induced to adipocytes for 8 days. Lipids
were extracted according to a previous protocol (Xu et al., 2012). Triglycerides content were
determined with reagent kits (Pointe Scientific, Inc, MI), and the absorbance was measured
spectrophotometrically at 520 nm. Relative triglycerides content (%) was displayed using
differentiation medium containing 0.1% DMSO - treated cells as a standard.

Author Manuscript

Glucose uptake assay
Glucose uptake in 3T3-L1 mature adipocytes was measured by using 2-[N-(7-nitrobenz-2oxa-1,3-diazol-4-yl) amino]-2-deoxy-d-glucose (2-NBDG) according to the manufacturer’s
instructions (Cayman Chemical Company, MI). In brief, 3T3-L1 preadipocytes plated on
96-well fluorescent plates were induced to adipocytes as described above. At Day11, cells
were washed with PBS and then treated with serum-free DMEM containing PFOS (0 – 100
µM) or DMSO (0.1%) for 5 hrs. Then cells were washed with sterilized PBS for 3 times, and
stimulated with 100 nM insulin for 20 mins in KRPH buffer (20 mM HEPES, 5 mM
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KH2PO4, 1 mM MgSO4, 1 mM CaCl2, 136 mM NaCl, and 4.7 mM KCl, pH 7.4) with the
presence of PFOS or DMSO, respectively. Glucose uptake was initiated by the addition of
100 µg/mL 2-NBDG to each well. The fluorescence activity was monitored at an excitation
wavelength of 485 nm and an emission wavelength of 535 nm. At least eight replicates for
each dosage was performed. Relative glucose uptake was displayed using vehicle-treated
group as a standard.
hPAP induction assay

Author Manuscript

Mouse embryonic fibroblast (MEF) differentiation to adipocytes was performed as
described elsewhere (Shin et al., 2007; Xu et al., 2012). MEFs were isolated from 13.5- to
15.5-d post coital mouse embryos from ARE-hPAP transgenic mice, then cells were
cultured in DMEM supplemented with 10% FBS in 10 cm culture dishes (Johnson et al.,
2002). MEFs were collected and cultured in 6-well plate, 2 days post of 100% confluence,
cells were switched to differentiated media with DMEM containing 10% FBS, 10 µg/mL
insulin, 1 µM DEX, 0.5 mM IBMX (Day0). Three days later, cells were switched to media
only containing 10% FBS and 10 µg/mL insulin for the remaining days. And four days post
differentiation, total RNA was extracted and the relative mRNA levels of hPAP were
measured using quantitative real-time PCR. The detailed design was described as Figure 1C.
Chromatin Immunoprecipitation (ChIP) assay

Author Manuscript

3T3-L1 cells were induced to adipocytes as described above. Two days post differentiation
to adipocytes, cells were harvested and the Chip assay was performed according to the
manufacturer’s instructions (Active Motif, Carlsbad, CA). Equal amount of sheared
chromatin DNA (15 µg) was incubated with anti-Nrf2 antibody (Cell Signaling, Danvers,
MA) or IgG as negative control overnight at 4 °C. A portion of sheared chromatin DNA was
preserved as input (10 µL). Purified DNA was PCR-amplified for 35 cycles (30 s at 94 °C,
30 s at 59 °C, and 30 s at 72 °C) with the primers that cover putative AREs sequences in
mouse Nqo-1 promoters (Forward: 5’-GCAGTTTCTAAGAGCAGAACG-3’; Reverse: 5’GTAGATTAGTCCTCACTCAGCCG-3’).
Statistical Analysis
Quantitative data were presented as average ± SE. Statistic differences were determined by a
one-way ANOVA followed by a Duncan’s Multiple Range post hoc test. All statistical tests
with P<0.05 were considered significant.

Results
Author Manuscript

PFOS induces adipogenesis in 3T3-L1 preadipocytes
In order to explore the association of PFOS exposure and adipocyte differentiation, we
determined the effect of PFOS concentrations on 3T3-L1 pre-adipocyte viability. No overt
toxicity was observed at <50 µM in the current study (Figure 1D). 3T3-L1 preadipocytes
were differentiated to adipocytes in the presence of differentiated cocktail with or without
PFOS. Oil Red O staining of mature lipid-containing adipocytes at Day8 was performed to
evaluate PFOS effects on adipogenesis. Figure 2A illustrates that high concentrations of
PFOS (1–100 µM) increased lipid accumulation in 3T3-L1 adipocytes compared to vehicleToxicol Appl Pharmacol. Author manuscript; available in PMC 2017 January 01.
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treated group (Figure 2A). However, staining was similar between vehicle- and PFOStreated groups treated with concentrations less than 1 µM (1–500 nM), except there was
lower lipid content at the dosage of 5 nM (Figure, 2B, Figure, S1). Similar to the observed
staining, higher PFOS concentrations (1–50 µM) increased triglycerides content in 3T3-L1
adipocytes by more than 20% above control, but this effect was not observed with the
relatively lower PFOS concentrations (1–100 nM) (Figure 2B). The data suggest that PFOS
has the potential to potentiate induction of mouse preadipocyte differentiation to mature
adipocytes and promote lipid accumulation.
PFOS increases adipogenic gene expression in 3T3-L1 preadipocytes
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The underlying molecular mechanisms for PFOS function on adipogenesis were evaluated.
3T3-L1 preadipocytes were induced to adipocytes with PFOS administration for continuous
3 days, total RNA was extracted and the relative mRNA levels of genes related with
adipogenesis of Cebpα, Pparγ, Fatty acid-binding protein 4 (Fabp4) and Lpl were
determined. There is no significant difference for these four genes expression between
vehicle- and PFOS-treated groups at Day1. After induction to adipocytes for 3 days (Day3),
Cebpα, Pparγ, Fabp4 and Lpl were significantly induced in both groups; with induction
being significantly higher in PFOS-treated adipocytes than vehicle-treated group (increased
by 32.2-, 14.2-, 8.6-, and 19.7-fold, respectively), suggesting PFOS increased adipogenic
gene expression, which may contribute to the increased adipogenesis (Figure 3A).
Additionally, the mRNA levels of Nrf2 and two target genes, NAD(P)H dehydrogenase,
quinone 1 (Nqo1) and Glutamate-cysteine ligase, catalytic subunit (Gclc) were determined.
At Day1, PFOS-treatment slightly decreased Nqo1 and Gclc mRNA levels compared to
vehicle-treated group. After 3 days of induction to adipocytes (Day3), PFOS significantly
increased Nrf2, Nqo1 and Gclc mRNA levels in 3T3-L1 adipocytes than vehicle-treated
group by more than 15-fold, suggesting that PFOS has the potential to activate Nrf2
signaling in preadipocytes (Figure 3B).
PFOS promotes insulin-stimulated glucose uptake in 3T3-L1 adipocytes
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In order to assess the metabolic consequence of PFOS treatment in 3T3-L1 preadipocytes,
insulin-stimulated glucose uptake were monitored in vehicle- and PFOS-treated adipocytes.
After 3T3-L1 preadipocytes were differentiated to adipocytes for 10 days, cells were
exposed to PFOS for 5 hrs, then 2-NBDG was added, and the fluorescence activity was
monitored. There was no significant difference between the low dose PFOS treatments (1
and 5 µM) and vehicle-treated group. However, insulin-stimulated glucose uptake was
significantly higher in PFOS-treated at the concentration of 10 µM than vehicle-treated
group (by 26%). And a dose-dependent increase of glucose uptake by PFOS-treatment was
observed, with the highest induction being at the dosage of 100 µM (61.0% higher than
vehicle) (Figure 4A). The gene expression related to insulin signaling and glucose
metabolism was monitored. Low dose PFOS treatment (1 µM) did not affect Pparγ, Sterol
regulatory element-binding protein 1 (Srebp1c), Glucose transporter type 4 (Glut4), Insulin
receptor substrate 1 (Irs-1), and Insulin Receptor (Insr) gene expression. However, treatment
with 10 or 50 µM PFOS increased Pparγ, Srebp1c, Glut4 and Irs-1 expression compared to
vehicle-treated group (by 1.3-, 1.8-, 1.7-, 1.4-and 1.2-, 1.3-, 1.2-, 1.2-fold, respectively), but
with similar Insr expression between vehicle- and PFOS-treated groups (Figure 4B). It was
Toxicol Appl Pharmacol. Author manuscript; available in PMC 2017 January 01.
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hypothesized that in the early induction process, PFOS might induce the antioxidant
response, then leading to Nrf2 activation that augmented Pparγ induction (Shi and Zhou,
2010). PFOS (1 µM) did not induce Nrf2 or Nqo1 expression, but expression was induced
by about 30% in cells treated with 10 and 50 µM PFOS, suggesting the potential role of
PFOS activating Nrf2 signaling in mature adipocytes (Figure 4C).
Adipogenic gene expression and Nrf2 signaling is increased in white adipose tissue from
mice administered PFOS
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C57BL/6 male mice were administered PFOS for 36 days (100 µg/kg/day) and the transcript
levels corresponding to adipogenesis and Nrf2 signaling were measured in epididymal
WAT. PFOS significantly increased the expression of adipogenic genes, including Cebpα,
Pparγ, Fabp4 and Lpl in WAT (by 66.4%, 93.2%, 73.3%, and 67.6%). Srebp1c and Insr,
related with insulin signaling, were significantly induced after PFOS administration (by
67.2% and 59.7%), along with the increasing tread of Glut4 and Irs-1 expression (by 44.1%
and 25.9%) (Figure 5A). Additionally, PFOS significantly induced Nrf2, Nqo1 and Gclc
mRNA levels (by 97.2%, 173.0% and 87.3%), suggesting enhanced Nrf2 signaling in WAT
of mice administrated with PFOS. Expression of Heme oxygenase 1 (Ho-1), Multidrug
resistance-associated protein (Mrp) 2, Mrp4, UDP-glucuronosyltransferase (Ugt) 1a6, and
Superoxide dismutase (Sod) 1, which are highly associated with Nrf2 signaling
(Thimmulappa et al., 2002; Dreger et al., 2009), were increased in the current study (37.6%,
26.0%, 334%, 65.2%, and 48.1% higher than vehicle-treated group). PFOS decreased
Cytochrome P450, family 7, subfamily A, polypeptide 1 (Cyp7a1) by 78.5%, which is
consistent with the previous study (Chang et al., 2009).
PFOS increased lipid accumulation in differentiated human visceral preadipocytes
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Human visceral preadipocytes were obtained and differentiated to adipocytes, and cellular
lipid content was evaluated by Oil red O staining. Eleven days post-differentiation, PFOS (5
and 50 µM) significantly increased staining in mature adipocytes (Figure 6A). Furthermore,
the stain was extracted and quantified spectrophotometrically. Figure 6B illustrates that
PFOS increased staining in adipocytes by 48% at 5 µM and 40% at 50 µM, suggesting PFOS
may increase adipogenesis in human visceral preadipocytes, contribute to enhance lipid
accumulation in PFOS-treated group (Figure 6B).
PFOS increases Antioxidant Response Element activity and enhances Nrf2 enrichment at
the ARE element in mouse Nqo1 promoter

Author Manuscript

Some recent work indicates that the Nrf2 pathway is inducible in MEFs and adipose tissue
(Shin et al., 2007; Xu et al., 2012). In order to determine whether PFOS induces Nrf2
signaling and might increase adipogenesis via the Nrf2 signaling pathway, MEFs from
ARE-hPAP transgenic mice (Johnson et al., 2002) were isolated and differentiated to
adipocytes with or without PFOS for 4 days. Next, hPAP mRNA levels were measured by
quantitative real-time PCR. PFOS treatment (50 µM) doubled hPAP mRNA levels compared
to vehicle controls (Figure 7), highly suggesting PFOS increased ARE binding activity
(Figure 7A). Furthermore, to determine whether the increased ARE binding was via the
increased Nrf2 binding in PFOS treatment, Chip assay was carried out. Figure 7B and 7C

Toxicol Appl Pharmacol. Author manuscript; available in PMC 2017 January 01.

Xu et al.

Page 9

Author Manuscript

illustrate that two days into differentiation, PFOS increased Nrf2 binding to ARE sites in
mouse Nqo1 promoter (by 31%), suggesting that Nrf2 binding was increased after PFOS
treatment during the differentiation process (Figure 7B, 7C).

Discussion

Author Manuscript

PFOS has been manufactured for over 60 years. Epidemiological studies and recent research
with PFOS primarily focuses on widespread exposure (Giesy and Kannan, 2001; Olsen et
al., 2005), hepatic effects in humans (Nelson et al., 2010), primates (Chang et al., 2012) and
rodents (Wan et al., 2012), and metabolic perturbations (Wan et al., 2012). However, PFOS
effects on adipogenesis or adipocyte health is largely undescribed, yet is of growing concern
because of the growing population of obese people worldwide. In the current study, we
demonstrated that PFOS augmented adipocyte differentiation, increased the expression of
key transcription factors of Pparγ and Cebpα involved in adipogenesis, and increased ARE
binding activity and activation of Nrf2 signaling, which increase the binding to promoters
for oxidative stress-related and adipogenic genes, suggesting the potential roles of PFOS
regulating white adipose tissue expansion and the related obesity.
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The activation of Pparγ by PFOS suggested that PFOS has Pparα-independent mechanism,
which is in agreement with the previous study (Rosen et al., 2010). PFOS increased liver
weight and caused modest hepatomegaly, which related with the activation of peroxisome
proliferator, consistent with the effects of Pparα activator WY14,643. Also, PFOS induced
both mouse and human Pparα activation, but exerted a greater level of induction of mouse
Pparα than human Pparα at similar concentrations (Takacs and Abbott, 2007). It has been
reported that PFOS increased Pparγ-luciferance reporter plasmid activity at the
concentration from 1 to 100 µM, with little toxicity at the concentration of 250 µM (Takacs
and Abbott, 2007), illustrated that the dosage of 50 µM used in the current study is the
optimal concentration for PFOS treatment in vitro.
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Pparγ activation is the key process for adipocyte differentiation in 3T3-L1 preadipocytes.
Pparγ is needed for adipose tissue formation in mice, and in a loss-of-function experiment,
adipocyte differentiation and WAT expansion was impaired, and did not develop glucose
intolerance and insulin resistance, suggesting the central role for adipogenesis (Jones et al.,
2005). We failed to observe WAT expansion in mice administered with PFOS (100 µg/kg/
day) for 36 days (Figure S2). This lack of effect could be explained by the relatively low
dose of PFOS has been used in the current study, but is consistent with other reports. Qazi et
al. have used 0.005% (W/W) dietary treatment of PFOS for 10 days with male mice,
resulted in significant reductions for serum cholesterol and triglycerides content (Qazi et al.,
2010). And male BALB/c mice fed with high-fat diet (HFD) with the exposure of PFOS at
the dose of 5 or 20 mg/kg/day for 14 days, exhibited reduced serum lipid and lipoprotein
content, but significantly increased hepatic lipid accumulation, probably via Pparαindependent pathway (Wang et al., 2014). Also, compared to liver, PFOS deposits to a much
lower concentration in WAT (Maestri et al., 2006). So perhaps the low dose of PFOS
administered might not have a positive induction in adipose tissue expansion in vivo, despite
this treatment inducing adipogenic gene expression at transcriptional levels. It was estimated
that the possible range of environmental exposure dosage for human in European countries
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such as Italy, the Netherlands, Sweden and the UK, was between 45 and 58 µg/kg/day based
on the mean consumption (Saikat et al., 2013). Dose of 100 µg/kg/day was used in the
current study, as planning to mimic the effects of environmental levels exposure of PFOS on
WAT expansion and the possible function on obesity in animal model of mice. The second
possible reason is that PFOS has a potential function to induce Pparα activation (Shipley et
al., 2004). Increased Pparα in adipose tissue could induce lipolysis and promote β-oxidation
(Reddy and Hashimoto, 2001; Goto et al., 2011), which is beneficial to prevent the lipid
accumulation to adipose tissue and decrease white adipose tissue mass. It was noted that
contradict results have been reported that PFOS administration reduced WAT mass, the
ventral fat was significantly reduced when mice treated with PFOS (20 mg/kg/day) for 14
days, even in normal diet and HFD-group, which related with the reduced secretion and
impaired function of low density lipoproteins (Wang et al., 2014).
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It is interesting to note that PFOS increased insulin-stimulated glucose uptake in
differentiated adipocytes. A previous study reported that higher serum PFOS concentration
was positively associated with increased serum insulin levels and insulin resistance (Lin et
al., 2009), which contrasts with the current study. And Nelson et al. reported that higher
serum PFOA and PFOS concentration was positively associated with serum cholesterol
levels, but displayed a weak association with body weight and insulin resistance (Nelson et
al., 2010). Another in vivo study performed on rats, which the pregnant rats were given with
PFOS (0.5 or 1.5 mg/kg/day) from gestation day 0 to postnatal day 21. The pups displayed
impaired glucose tolerance and enhanced insulin resistance index, suggesting PFOS
disrupted insulin signaling in integrate animal study (Lv et al., 2013). In the current in vitro
study, we demonstrated that PFOS increased insulin-induced glucose uptake and increased
gene expression related to insulin signaling. One possible reason is that PFOS increased
adipogenesis in 3T3-L1 preadipocytes and enhanced adipogenesis increases capacity for
glucose uptake (Nugent et al., 2001). Also, enhanced Pparγ and Glut4 expression will help
to promote glucose uptake, as well as improve insulin signaling and insulin-response
activity. Our previous study reported that enhanced Nrf2 activity by Keap1-KD increased
glucose tolerance, and increased insulin-stimulated Akt phosphorylation without Glut4
expression change (Xu et al., 2013), suggesting activation Nrf2 can promote insulin
signaling, contribute to positively regulate glucose uptake in differentiated 3T3-L1
preadipocytes.

Author Manuscript

The study herein reported that PFOS could induce Nrf2 activation in preadipocytes. PFOS
administration has been shown to increase ROS production, which induces oxidative stress
and activate Nrf2 signaling (Qian et al., 2010). ARE consensus elements are the typical
transcriptional factor binding sites, which are described to induce the antioxidant gene
expression for Nrf2 target genes, such as Ho1, Gclc, Nqo1, and Mrps to provide a protective
role against oxidative and cytochemical stress (Nguyen et al., 2009). Also, ARE sites have
been reported in the promoter of Pparγ and Cebpα, which are responsible for 3T3-L1
preadipocytes adipogenesis (Pi et al., 2010). ARE binding was enhanced after PFOS
treatment in MEFs isolated from transgenic mice that harbor a ARE sequence coupled to a
hPAP reporter, suggesting activation of genes via ARE sites is a process that occurs via
PFOS-induced adipogenesis. Chip assay revealed that PFOS treatment increased Nrf2
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binding to ARE sites in the mouse Nqo1 promoter in 3T3-L1 cells cultured in induction
media for 4 days, further confirming that PFOS administration can induce Nrf2 signaling via
ARE binding during adipogenesis.
Overall, this study reported that novel effects of PFOS in inducing Pparγ and Cebpα
expression and adipogenesis, via enhancing ARE binding activity and Nrf2 signaling in
preadipocytes (Figure 7D). Additionally, PFOS increased insulin-stimulated glucose uptake
and increased gene expression related with insulin signaling. This study points out the
potential roles of PFOS promoting adipose tissue differentiation and the related metabolic
conditions of obesity consequentially.
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Highlights
●

PFOS induces adipogenesis in association with increased Pparγ and Cebpα
mRNA expression

●

PFOS increases ARE bindingactivity and activates Nrf2 signaling

●

PFOS increases insulin-stimulated glucose uptake
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Figure 1. MTT assay of PFOS on 3T3-L1 preadipocytes

The illustration of study design on (A) 3T3-L1 preadipocytes, (B) human visceral
preadipocytes, and (C) mouse embryonic fibroblasts. (D) 3T3-L1 preadipocytes were
exposed to PFOS at concentration of 1 nM, 5 nM, 10 nM, 100 nM, 500 nM, 1 µM, 5 µM, 10
µM, 50 µM, 100 µM or DMSO in DMEM with 10% FBS for 48 hrs. PFOS toxicity at
different dosage was determined by MTT assay. Data for vehicle-treated group was
considered as 100%. N=5. *, P<0.05, PFOS-treated vs. vehicle (Veh).
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Figure 2. Non-cytotoxic levels of PFOS enhances lipid content in differentiated 3T3-L1
preadipocytes

Cells were differentiated 2 days post 100% confluences (Day0) by switching with
differentiated media containing 10 µg/mL insulin, 1 µM dexamethasone, 0.5 mM
isobutylmethylxanthine in DMEM with 10% FBS for the first 3 days; then switch to media
only containing 10 µg/mL insulin in DMEM with 10% FBS for the additional 5 days.
Indicated concentration of PFOS or vehicle was included in media from Day0 to Day8. (A)
Representative images of Oil red O staining of 3T3-L1 preadipocytes at indicated

Toxicol Appl Pharmacol. Author manuscript; available in PMC 2017 January 01.

Xu et al.

Page 17

Author Manuscript

concentration of PFOS. (B) Lipids were extracted from differentiated 3T3-L1 adipocytes by
using chloroform/ methanol mixture, and triglycerides (TG) content was determined
spectrophotometrically. Relative triglycerides content (%) was displayed using differentiated
media containing DMSO (0.1%) - treated cells as a standard (Veh). *, P<0.05, PFOS-treated
vs. vehicle (Veh).
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Figure 3. PFOS increases adipogenic gene expression and induced Nrf2 signaling in 3T3-L1
preadipocytes

3T3-L1 preadipocytes were induced to differentiation to adipocytes with or without PFOS
(50 µM) for 3 days. Total RNA was extracted at the indicated time. Relative mRNA levels
were quantified by quantitative real-time PCR. PFOS increased adipogenic gene expression
of Cebpα, Pparγ, Fabp4, Lpl (A), and increased Nrf2 signaling of Nrf2, Nqo1, Gclc (B)
mRNA levels in 3T3-L1 preadipocytes All data were normalized to 18S rRNA levels. *,
P<0.05, PFOS-treated vs. vehicle (Veh)..
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Figure 4. PFOS promotes insulin-stimulated glucose uptake in 3T3-L1 adipocytes
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(A) 3T3-L1 preadipocytes were induced to differentiation to adipocytes for 10 days, then
treated with PFOS (1, 5, 10, 50, 100 µM) for 5 hrs. Glucose uptake of differentiated 3T3-L1
preadipocytes was determined by using 2-NBDG according to the manufactory instruction.
The fluorescence activity was monitored at an excitation wavelength of 485 nm and an
emission wavelength of 535 nm. Relative glucose uptake was displayed using vehicletreated group as a standard. Total RNA was extracted from 3T3-L1 adipocytes after treated
with PFOS (10 or 50 µM) for 5 hrs. Relative mRNA levels of (B) Pparγ, Srebp1c, Glut4,
Irs-1, Insr and (C) Nrf2, Nqo1 were quantified by quantitative real-time PCR. All data were
normalized to 18S rRNA levels. *, P<0.05, PFOS-treated vs. vehicle (Veh).
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Figure 5. Adipogenic gene expression and Nrf2 signaling of Nrf2 and Nqo1 expression increase
in white adipose tissue from mice administered PFOS

Mice were administrated with PFOS (100 µg/kg/day) for 36 days. Epididymal white adipose
tissue was collected and total RNA was extracted. (A, B) Relative mRNA levels of the
indicated gene were quantified by quantitative real-time PCR. All data were normalized to
18S rRNA levels. *, P<0.05, PFOS-treated vs. vehicle (Veh).

Toxicol Appl Pharmacol. Author manuscript; available in PMC 2017 January 01.

Xu et al.

Page 21

Author Manuscript
Author Manuscript
Author Manuscript

Figure 6. PFOS increased lipid accumulation in differentiated human visceral preadipocytes
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Human visceral preadipocytes obtained from Lonza were induced to differentiation to
adipocytes by switch with the differentiated media contain dexamethasone,
isobutylmethylxanthine and insulinSingleQuots™ according to the manufacturer’s
instructions, with PFOS (5 or 50 µM) or not (0.1% DMSO) for 11 days. (A) Representative
images of Oil red O staining of differentiated human visceral preadipocytes treated with
PFOS at indicated concentration. (B) Staining of lipids was extracted from differentiated
human visceral preadipocytes via isopropanol isolation, and the lipid content was
determined spectrophotometrically. Relative lipid content (%) was displayed using
differentiated media containing DMSO (0.1%) -treated cells as a standard (Veh). *, P<0.05,
PFOS-treated vs. vehicle (Veh).
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Figure 7. FFOS increases hPAP expression and enhances Nrf2 enrichment at ARE sites in mouse
Nqo1 promoter

(A) Mouse embryonic fibroblasts isolated from ARE-hPAP transgenic mice were induced to
differentiation to adipocytes for 4 days, then incubated with PFOS (50 µM) for additional 4
days. Total RNA was extracted and hPAP mRNA levels were quantified by quantitative
real-time PCR. All data were normalized to 18S rRNA levels. *, P<0.05, PFOS-treated vs.
vehicle (Veh). (B) 3T3-L1 cells were induced to differentiation for 2 days. Cells were
collected for Chromatin immunoprecipitation assays using either Nrf2 antibody or IgG as
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the negative control. A primer targeted for antioxidant response element in mouse Nqo1
promoter was used for PCR amplification. Non-immunoprecipitated chromation (1%) was
used as an input control. (C) Relative chip signal for PFOS function on Nrf2 enrichment to
ARE element of mouse Nqo1 promoter. (D) The work flow for PFOS increased
adipogenesis via activating Nrf2 signaling and inducing Cebpα, Pparγ expression in
preadipocytes.
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